Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, LADs with GGO were correlated with a lower incidence of PD-L1 expression than pure-solid tumors.
|
31500267 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor cells in the context of solid tumor treated with checkpoint inhibitors targeting the PD-1 pathway represents an issue for clinical research.
|
26086854 |
2015 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Purpose:</b> We conducted this study to determine the relationship between PD-1/PD-L1 inhibitors and the incidence risk of peripheral neuropathy in patients with solid tumors.
|
31552184 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Solid tumors with CD8 T-cell rich tumor microenvironment have been implicated to be associated with increased PD-L1 expression.
|
27465786 |
2016 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Recently, US Food and Drug Administration approved anti-PD-L1 immunotherapy for solid tumors with deficient mismatch repair (MMR).
|
30633926 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
|
30515672 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Programmed death ligand 1 (PD-L1) has shown potential as a therapeutic target in numerous solid tumors.
|
29378617 |
2018 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients.
|
27939400 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, the response rates of anti-PD-L1 have been limited in several solid tumors.
|
31668929 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This study evaluated ibrutinib plus durvalumab, a PD-L1-targeting antibody, in patients with relapsed/refractory solid tumors.
|
31230047 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Purpose The anti-programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death ligand-1 (PD-L1)-positive advanced solid tumors.
|
29116900 |
2018 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Our study demonstrated the utility of exploring the expression of two potentially targetable immune checkpoint proteins (PD-1/PD-L1) in a substantial proportion of solid tumors, including some aggressive subtypes that lack other targeted treatment modalities.
|
25392179 |
2014 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immune checkpoint inhibitors such as anti-cytotoxic T lymphocyte antigen-4 or anti-programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have demonstrated durable response rates across a broad range of solid tumors, including NSCLC, which has revolutionized the treatment of solid tumors.
|
30612418 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
An Annexin V/PI double staining assay further showed that B7-H1 expressed by SP6.5 cells did not increase the apoptosis of T-cells, though it was found in a variety of other solid tumors.
|
21461580 |
2011 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our findings also suggest TET activity as a biomarker for predicting the efficacy and patient response to anti-PD-1/PD-L1 therapy, and stimulating TET activity as an adjuvant immunotherapy of solid tumors.
|
31310587 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Primary end points were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS).
|
31046082 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A cohort of patients with advanced, PD-L1-positive SGC was enrolled in the nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors (KEYNOTE-028; NCT02054806).
|
29462123 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck cancer, classical Hodgkin lymphoma, colorectal cancer, gastroesophageal cancer, hepatocellular cancer, and other solid tumors.
|
31584451 |
2020 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We carried out this systematic meta-analysis to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors.
|
28938692 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.
|
29069824 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immunotherapy has moved to the center stage of cancer treatment with the recent success of trials in solid tumors with PD-1/PD-L1 axis blockade.
|
28213726 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Many additional ongoing trials were identified evaluating the use of PD-(L)1 inhibitors for the management of solid tumors.
|
28971749 |
2017 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
As PD-1/PD-L1 immune checkpoint inhibitors exhibited promising clinical outcomes in various types of solid tumors, PD-1/PD-L1 blockades have been explored for the treatment of hepatocellular carcinoma (HCC).
|
29028787 |
2018 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Coprimary endpoints were investigator-assessed progression-free survival per Response Evaluation Criteria in Solid Tumors version 1.1 and overall survival, assessed in the intention-to-treat population and in patients with PD-L1 immune cell-positive tumours (tumours with ≥1% PD-L1 expression).
|
31786121 |
2020 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Monoclonal antibodies (mAbs) directed against PD-1/PD-L1 have recently entered the therapeutic algorithm of several solid tumors.
|
28595514 |
2017 |